I read with interest the review article 'Delirium uncovered' in the January edition of JICS. 1 I agree with the authors that delirium is an extremely important issue in the ICU and one that is underappreciated. During the writing of the article, the authors may not have been aware that the Society of Critical Care Medicine (SCCM) were in the process of reviewing their guidance on delirium. Thus the statement on page 57 that haloperidol is recommended by the SCCM for the pharmacological treatment of delirium is now incorrect, 2 with the authors of this recent guidance saying: 'In the previous version of these guidelines, the recommended use of haloperidol for the treatment of delirium was a Level C recommendation based only on a case series. These data did not meet the evidence standard for this version of the guidelines ... There is no published evidence that treatment with haloperidol reduces the duration of delirium in adult ICU patients ... We suggest that in adult ICU patients with delirium unrelated to alcohol or benzodiazepine withdrawal, continuous IV infusions of dexmedetomidine rather than benzodiazepine infusions be administered for sedation to reduce the duration of delirium in these patients.' In my view it remains unclear whether dexmedotomidine is those who are apparently performing poorly to further analyse their data, seek out measures to improve care if necessary and aim to offer patients the best of care wherever they are treated?
Intensive care-led echocardiography and FICE accreditation
W e read the article by Dr Alam and colleagues with interest as it reports the feasibility and utility of an echocardiography service performed by intensivists. 1 Doctors delivering this service were all BSE-accredited in transthoracic echocardiography (TTE) and performed full studies in 96% of cases. This impressive level of qualification and practice is unusual among non-cardiologists because the required logbook case mix for TTE-accreditation is difficult to obtain outside a dedicated Fellowship and may not always reflect their routine clinical practice.
Clinical questions that intensivists ask are often quite different to those of the cardiac physiologist, which is why the Intensive Care Society and British Society of Echocardiography have developed the Focused Intensive Care Echo (FICE) and Advanced Critical Care Echo (ACCE) training programmes. 2 Since the launch of FICE in November 2012 it has received considerable interest from the UK intensive care community and has an ever-expanding network of registered mentors nationwide. Designed to be deliverable within a six-month period and reinforced by rigorous governance with mentorship, supervision and triggered assessment, FICE covers relevant subjects like hypovolaemia, fluid-responsiveness and the bedside diagnosis of shock. FICE-approved mentors and courses can be found on the ICS website. 3 Echocardiography has much to add to the diagnosis and haemodynamic assessment of critically ill patients and is likely to become a core skill for intensivists of the future. We congratulate Dr Alam and colleagues for introducing such a service and invite all potential candidates and mentors to register with FICE and potentially do the same in years to come. 3 1 published January 24th, he is quite correct that the most recent Society of Critical Care Medicine comprehensive sedation guidelines, 2 launched on January 2013, do not go so far as their original guidelines, ie "haloperidol was the preferred agent for the treatment of delirium in the critically ill patient." 3 Rather there is a statement 'there is no published evidence that treatment with haloperidol reduces the duration of delirium in adult ICU patients.' They go on to discuss the risks of drugs that prolong the QTc which suggests that they are not dismissing haloperidol, but leaving clinicians to make their own minds up, which in fact has always been the case. We consider haloperidol a useful agent to manage the agitated delirious ICU patient and the majority of UK ICU consultants would appear to agree with us according to an Intensive Care Foundation survey published in 2010. 4 Regarding the use of dexmedetomidine infusions, the statement Dr Danbury quotes is the answer to the question asked of the panel "For mechanically ventilated, adult ICU patients with delirium who require continuous IV infusions of sedative medications, is dexmedetomidine preferred over benzodiazepines to reduce the duration of delirium?". This does not include the option of using an alternative agent such as propofol which is the obvious first-line alternative. We know benzodiazepines are deliriogenic and agree that the routine use of benzodiazepine infusions need to be questioned, but not necessarily removed entirely. 5 The MIDEX and PRODEX studies referred to comparing midazolam, propofol and dexmedetomidine interestingly (and disappointingly) did not monitor delirium in a meaningful way and as such do not add to the evidence base regarding dexmedetomidine and ICU delirium. Until more evidence is available, we are of the view that the routine use of dexmedetomidine in ICU patients who have delirium cannot be justified.
